Mina Sarah Ally1, Sumaira Aasi1, Ashley Wysong2, Claudia Teng1, Eric Anderson3, Irene Bailey-Healy1, Anthony Oro1, Jinah Kim4, Anne Lynn Chang1, Jean Yuh Tang5. 1. Department of Dermatology, Stanford University, Stanford, California. 2. Department of Dermatology, Stanford University, Stanford, California; Scripps Clinic, Dermatologic Surgery Division, La Jolla, California. 3. School of Medicine, Stanford University, Stanford, California. 4. Department of Dermatology, Stanford University, Stanford, California; Department of Pathology, Stanford University, Stanford, California. 5. Department of Dermatology, Stanford University, Stanford, California. Electronic address: tangy@stanford.edu.
Abstract
BACKGROUND: Vismodegib is an oral hedgehog-pathway inhibitor approved for advanced basal cell carcinoma (BCC). Although most BCCs are amenable to surgery, excision of large tumors in aesthetically sensitive sites may compromise function or cosmesis. OBJECTIVE: We sought to evaluate the reduction in BCC surgical defect area after 3 to 6 months of neoadjuvant vismodegib. METHODS: This was an open-label, single-arm intervention trial with a primary outcome of change in target-tumor surgical defect area pre- and post-vismodegib (150 mg/d). Secondary outcomes were change in tumor area and tolerability. RESULTS: Eleven of 15 enrolled patients, aged 39 to 100 years, completed the trial. Thirteen target tumors were excised after a mean of 4±2 months of vismodegib. In all, 29% (4 of 14 patients) could not complete more than 3 months because of vismodegib-related side effects. The mean baseline target-tumor diameter was 3.2 cm, and 10 of 13 tumors occurred on the face. Overall, vismodegib reduced the surgical defect area by 27% (95% confidence interval -45.7% to -7.9%; P=.006) from baseline. Vismodegib was not effective in patients who received less than 3 months. Over a mean follow-up of 11.5 (range 4-21) months for all tumors, only 1 tumor recurred at 17 months post-Mohs micrographic surgery. LIMITATIONS: Short follow-up time and no placebo control are limitations. CONCLUSION: Neoadjuvant vismodegib appears to reduce surgical defect area when taken for 3 months or longer for nonrecurrent BCCs in functionally sensitive locations. Further studies with larger sample sizes and long-term follow-up are warranted.
BACKGROUND: Vismodegib is an oral hedgehog-pathway inhibitor approved for advanced basal cell carcinoma (BCC). Although most BCCs are amenable to surgery, excision of large tumors in aesthetically sensitive sites may compromise function or cosmesis. OBJECTIVE: We sought to evaluate the reduction in BCC surgical defect area after 3 to 6 months of neoadjuvant vismodegib. METHODS: This was an open-label, single-arm intervention trial with a primary outcome of change in target-tumor surgical defect area pre- and post-vismodegib (150 mg/d). Secondary outcomes were change in tumor area and tolerability. RESULTS: Eleven of 15 enrolled patients, aged 39 to 100 years, completed the trial. Thirteen target tumors were excised after a mean of 4±2 months of vismodegib. In all, 29% (4 of 14 patients) could not complete more than 3 months because of vismodegib-related side effects. The mean baseline target-tumor diameter was 3.2 cm, and 10 of 13 tumors occurred on the face. Overall, vismodegib reduced the surgical defect area by 27% (95% confidence interval -45.7% to -7.9%; P=.006) from baseline. Vismodegib was not effective in patients who received less than 3 months. Over a mean follow-up of 11.5 (range 4-21) months for all tumors, only 1 tumor recurred at 17 months post-Mohs micrographic surgery. LIMITATIONS: Short follow-up time and no placebo control are limitations. CONCLUSION: Neoadjuvant vismodegib appears to reduce surgical defect area when taken for 3 months or longer for nonrecurrent BCCs in functionally sensitive locations. Further studies with larger sample sizes and long-term follow-up are warranted.
Authors: Vinodh Kakkassery; Steffen Emmert; Irenäus A Adamietz; György Kovács; Anselm M Jünemann; Caroline Otte; Michael Zimbelmann; Anton Brosig; Salvatore Grisanti; Ludwig M Heindl Journal: Ophthalmologe Date: 2020-02 Impact factor: 1.059
Authors: V Kakkassery; K U Loeffler; M Sand; K R Koch; A M Lentzsch; A C Nick; I A Adamietz; L M Heindl Journal: Ophthalmologe Date: 2017-03 Impact factor: 1.059
Authors: John Paoli; Johan Dahlén Gyllencreutz; Julia Fougelberg; Eva Johansson Backman; Maja Modin; Sam Polesie; Oscar Zaar Journal: Dermatol Pract Concept Date: 2019-04-30
Authors: Alon Kahana; Shelby P Unsworth; Christopher A Andrews; May P Chan; Scott C Bresler; Christopher K Bichakjian; Alison B Durham; Hakan Demirci; Victor M Elner; Christine C Nelson; Denise S Kim; Shannon S Joseph; Paul L Swiecicki; Francis P Worden Journal: Oncologist Date: 2021-05-31